Oncoinvent (ONCIN) Investor update summary

Operational progress

• Enrolled 71 patients by end-Q3, ~2/3 of the target, including 44 YTD and 16 in Q3; recruitment held near Q2 pace despite a two-week maintenance closure.

• 11 active recruiting sites, with five added YTD across Italy, the UK, Spain and Belgium; protocol amendments lowered inclusion thresholds and supported recruitment.

• Q4 recruitment tracked at a similar pace, with 2026 priorities on track.

Scientific activity and leadership

• Normal-tissue dosimetry results published in the Journal of Nuclear Medicine; three abstracts presented at ESMO and EANM.

• Dr Zuzana Jirakova Trnkova appointed CMO, bringing 20+ years of drug-development experience, including Phase III and alpha-emitter radiopharmaceuticals.

Financing and runway

• September private placement and retail offering raised NOK 148.5m gross; cash was NOK 200m at end-September, extending runway into H2 2027 and beyond the April 2027 interim readout.

• Spend reached NOK 110m by end-Q3; monthly burn was in the low teens and stable versus the start of the year despite increased recruitment.

• Proceeds support Phase II completion, FDA and EMA alignment, Phase III planning, manufacturing scale-up and early trial-start activities.

• A second manufacturing location through a CDMO, likely in the US, is planned to de-risk supply; Phase III funding may involve equity or strategic/pharma partners.